14 Aug 2025
ZERO Biotech was honored to attend the technology launch conference held jointly by Tsinghua University and PanMediso, alongside distinguished Hong Kong institutions including The Hong Kong Polytechnic University (PolyU) and Hong Kong Sanatorium & Hospital (HKSH). The event marked a significant breakthrough in the production of Actinium-225 (Ac-225), a rare medical isotope crucial for targeted alpha therapy in cancer treatment.
The presence of key Hong Kong healthcare and academic institutions at the signing ceremony underscores the growing collaboration between Hong Kong and Mainland China in advanced medical research and development. This partnership exemplifies the unique role Hong Kong plays in bridging international nuclear medicine expertise with Mainland China's technological capabilities.
Comparing to the current mainstream beta-emitting therapeutic isotopes such as Lutetium 177 (Lu-177), Ac-225 emits alpha-particles that carry higher energy and result in stronger localized DNA damage to cancer cells. The radiation range is shorter that it spares surrounding healthy tissue, making it a more promising isotope against cancers resistant to beta emitting therapies.
As the operator of the only full-licensed central radiopharmacy for therapeutic radiopharmaceuticals in Hong Kong supplying critical life-saving drugs to major local hospitals, ZERO Biotech recognizes this achievement will benefit the company for advancing radiopharmaceutical development and clinical applications of their targeted alpha therapy development. The company is ready to help bring these innovative treatments to patients who need them most.